Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2024 08:30 ET | Source: Eterna Therapeutics

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

Eterna Launches Research to Evaluate its Lead iMSC Therapy Candidate’s Ability to Induce and Modulate Antitumor Immunity in Ovarian and Breast Models